Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected to reach target enrollment (n=300) in April 2026, with topline results expected in the third quarter of 2026 Phase 2 IRIS trial for ML-004 for autism spectrum disorder has completed enrollment, with topline results expected in the third quarter of 2026 Received FDA Fast Track designation for ML-007C-MA for Alzheimer’s disease psychosis; topline results from Phase 2 VISTA trial expected in the second half of 2027 Expanded pipeline with a next-generation M1/M4 muscarinic agonist program, ML-055, with candidate nomination expected in 2026 Ended the year with $453.1 million in cash, cash equivalents and investments, which is expected to fund operations through 2027SAN FRANCISCO and BOSTON, March 26, 2026 (GLOBE NEWSWIRE) — MapLight Therapeutics, Inc. (Nasdaq: MPLT), a...

Five Diversified, Ramping DeFi Business Lines Delivered Growth Exceeding Q4 Guidance Treasury Exceeds 1.93M HYPE, 1.92M KNTQ, & 1.00M HPL Tokens as of March 23(14) HYPD’s Unique “Triple-Dip” HYPE Deployment Generated ~3x Base Staking Income in Q4 Announces Executed LOI to Monetize the Optejet, With Potential Closing in Q2’26 LAGUNA HILLS, Calif., March 26, 2026 (GLOBE NEWSWIRE) — Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “Company”), the first U.S. publicly listed DeFi company building on Hyperliquid, today reported results for the fourth quarter and full year ending December 31, 2025. “Against a backdrop of significant market volatility, we are pleased to report rapid growth in our DeFi operating businesses which exceeded our guidance in the fourth quarter,” said Hyunsu Jung, CEO of Hyperion DeFi. Mr. Jung...

– Company to pursue Phase 3 development strategy designed to deliver best-in-class efficacy with a high-dose quarterly regimen in broad patient populations in both severe asthma and CRSwNP – – Company plans to initiate dosing in Phase 3 trials in both severe asthma and CRSwNP in Q1 2027 – – Reported positive top-line results from Phase 2 VALIANT trial of verekitug in patients with severe asthma in February 2026, demonstrating significant improvements in asthma exacerbations and lung function – – Presented additional analyses from Phase 2 VIBRANT trial at AAAAI, reinforcing verekitug’s therapeutic potential in CRSwNP – – Strong cash position of $341.5 million expected to fund planned operations through 2027 – WALTHAM, Mass., March 26, 2026 (GLOBE NEWSWIRE) — Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments...

BETHESDA, Md., March 26, 2026 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the fourth quarter and year ended December 31, 2025, and provided a corporate update. “We are encouraged by the progress made in 2025, as we made important advancements related to both the scientific understanding and clinical development of our lead candidate GT-02287, in development for the treatment of Parkinson’s disease with or without a GBA1 mutation. The promising impact GT-02287 has on the causative biology of Parkinson’s disease has been further elucidated from the analysis of functional and biomarker changes from the Phase 1b study,”...

Q4 FY26 Net Sales Increased 2.7% to $248.0 million vs. Q4 FY25 FY26 Net Sales Increased 2.4% to $697.1 million vs. FY25Announces New $40 million Share Repurchase Authorization STAMFORD, Conn., March 26, 2026 (GLOBE NEWSWIRE) — The Lovesac Company (Nasdaq: LOVE) (“Lovesac” or the “Company”), the Designed for Life home and technology brand best known for its Sactionals, The World’s Most Adaptable Couch, today announced financial results for the fourth quarter and full year fiscal 2026, which ended February 1, 2026. Shawn Nelson, Chief Executive Officer, stated, “Fiscal 2026 was a pivotal year for Lovesac. We made substantial progress on our evolution from a product-driven company into a multi-platform, multi-room, lifestyle brand. A brand that we believe can be the most loved home brand in America in short order, and one day,...

All figures are in Canadian dollars unless otherwise stated. BELO HORIZONTE, Brazil and SINGAPORE, March 26, 2026 (GLOBE NEWSWIRE) — Verde AgriTech Ltd (TSX: NPK | OTCQX: VNPKF) (“Verde” or the “Company”), today reported its operating and financial results for the fourth quarter and fiscal year ended December 31, 2025 (“Q4 2025” and “FY 2025”). “The Great Brazilian Agriculture Crisis continued to weigh on sales throughout 2025, and the sharp rise in judicial recovery filings across Brazil’s agribusiness sector shows how stressed the market remains. Since the crisis began in 2023, Verde has maintained a highly restrictive credit approval policy, prioritizing receivables quality, liquidity preservation and commercial discipline over volume at any cost. We believe this has been the right approach to protect the Company and preserve...

RALEIGH, N.C., March 26, 2026 (GLOBE NEWSWIRE) — Lumexa Imaging (Nasdaq: LMRI), one of the nation’s largest providers of outpatient imaging services, today announced certain financial results for the fourth quarter ended December 31, 2025, and reiterated full year 2026 guidance. The financial results included in this release pertaining to the fourth quarter and full year 2025 are preliminary, unaudited, and subject to final review and adjustment. “The fourth quarter of 2025 marked a strong close to an important year for Lumexa Imaging, with continued momentum across the business,” said Caitlin Zulla, Chief Executive Officer of Lumexa Imaging. “Strong Adjusted EBITDA growth was driven by advanced imaging volumes, ramping new de novo centers, and our return in-network with a large payer in New Jersey. We strengthened our balance sheet,...

Strengthening revenue trajectory — Robotaxi revenues rose by 160% year-over-year in Q4, with fare-charging revenues surging by over 500%. Accelerating fleet and geographic expansion — Robotaxi scaling accelerated as fleet size surpassed 1,400 units1, extending operational footprint to Croatia, Hangzhou and Changsha, with a target of reaching more than 20 cities by year-end 2026. Validating Unit Economics — Achieved consecutive UE breakeven in Guangzhou and Shenzhen within just four months of the Gen-7 Robotaxi launch. In Shenzhen, the daily net revenue per Gen-7 vehicle on the record peak day reached an all-time high of RMB394, with 25 orders per vehicle2.NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) — Pony AI Inc. (“Pony.ai” or the “Company”) (NASDAQ: PONY; HKEX: 2026), a global leader in achieving large-scale mass production and...

Net profit increases by 31.7% to EUR 26.6m in 2025, expected at EUR 30m for 2026 Significantly improved asset quality, with credit losses down 15.4% Dividend proposal of EUR 0.55 per share to the upcoming Annual General Meeting, up 25% from last year (2024: EUR 0.44 per share)Zug, 26 March 2026 – Multitude AG, a listed European FinTech company, offering digital lending and online banking services to consumers, SMEs, and institutional clients, (“Multitude”, “Company” or “Group”) has published its Group’s Annual Report, Corporate Governance Statement, ESG and Remuneration Report for the financial year ended 31 December 2025 on the Company’s website today. With its audited financial statements, Multitude confirms its positive preliminary results published on 12 March 2026 for the financial year 2025. Multitude has achieved its financial...

CSGFull Year 2025 Results Statement Topline Outperformance; Margins in Line with IPO OutlookFY 2026 Guidance ReaffirmedFinancial highlightsRevenue increased to €6.7bn, up 71.7% year on year (30.1% pro forma1), driven by strong demand across Defence Systems and the integration of The Kinetic Group Total backlog reached €15bn with a pipeline of €27bn, providing strong multi-year visibility Adjusted Operating EBIT2 increased to €1.6bn, up 60.7% year on year (31.2% pro forma), with margin at 24.1%   Net Profit from Continuing Operations increased to €872m, up 35.5% year on year Pre-tax Operating Cash Flow2 of €61m, reflecting the Q4 seasonal unwind of working capital as deliveries under contracted orders were executed Capex Intensity of 3.3%, supporting growth while maintaining capital discipline Net Debt of €3.0bn, with Net Debt to LTM...